All In Biotech

Drug Trial Radar · NCT03809429

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

A Randomised, Controlled, Open Label, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of Individualised FE 999049 (Follitropin Delta) Dosing, Using a Long GnRH Agonist Protocol and a GnRH Antagonist Protocol in Women Undergoing Controlled Ovarian Stimulation

Last checked: Nov 19, 2026Latest source record: May 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

437

Actual

Start

Apr 29, 2019

Primary completion

Feb 16, 2022

Study completion Feb 16, 2022

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.

Conditions

  • Infertility, Female

Interventions

  • FE 999049 + GnRH agonist (GONAPEPTYL)Drug

    Pre-filled injection pen

  • FE 999049 + GnRH antagonist (CETROTIDE)Drug

    Powder and solvent for solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Oocytes RetrievedTime frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Das Kinderwunsch Institut Schenk GmbH

    Dobl, Austria

  • Kepler University Hospital Linz

    Linz, Austria

  • Kinderwunschzentrum Goldenes Kreuz Privatklinik

    Vienna, Austria

  • Rigshospitalet

    Copenhagen, Denmark

  • Hillel Yafe Medical Center

    Hadera, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Beilinson Hospital Rabin Medical Center

    Petah Tikva, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Dipartimento della Donna, del bambino e delle malattie urologiche

    Bologna, Italy

  • European Hospital

    Roma, Italy

  • St. Elisabeth Ziekenhuis

    Tilburg, Netherlands

  • Isala Fertility Center

    Zwolle, Netherlands

  • Oslo University Hospital

    Oslo, Norway

  • Sykehuset Telemark HF

    Porsgrunn, Norway

  • Medicus AS

    Trondheim, Norway

  • Gyn-A.R.T. AG

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.